This document was prepared (in March-September, 2020) by and for MGH medical professionals (a.k.a. clinicians, care givers) and is being made available publicly for informational purposes only, in the context of a public health emergency related to COVID-19 (a.k.a. the coronavirus) and in connection with the state of emergency declared by the Governor of the Commonwealth of Massachusetts and the President of the United States. It is neither an attempt to substitute for the practice of medicine nor as a substitute for the provision of any medical professional services. Furthermore, the content is not meant to be complete, exhaustive, or a substitute for medical professional advice, diagnosis, or treatment. The information herein should be adapted to each specific patient based on the treating medical professional’s independent professional judgment and consideration of the patient’s needs, the resources available at the location from where the medical professional services are being provided (e.g., healthcare institution, ambulatory clinic, physician’s office, etc.), and any other unique circumstances. This information should not be used to replace, substitute for, or overrule a qualified medical professional’s judgment.

This website may contain third party materials and/or links to third party materials and third party websites for your information and convenience. Partners is not responsible for the availability, accuracy, or content of any of those third party materials or websites nor does it endorse them. Prior to accessing this information or these third party websites you may be asked to agree to additional terms and conditions provided by such third parties which govern access to and use of those websites or materials.
Clinical trials team considers EUA RDV and clinical trial candidacy

Eligible, willing, and able to enroll in a clinical trial?

Enrolled in clinical trial?

Trial includes RDV, or specifically excludes RDV

Oxygen saturation on ambient air ≤94% and on supplemental oxygen

Floor

ICU

Patient’s location of care

Yes

No

1. Download RDV information sheet
2. Obtain and document assent from patient or proxy
3. If assent documented, write order

Supportive care and close monitoring
Repeat labs at regular intervals
If progresses to Tier 1 and becomes candidate for RDV, contact ID consult pager

Strongly consider dexamethasone 6 mg PO/IV daily for up to 10 days
Consider statin if CV indication
Supportive care, close monitoring, repeat labs at regular intervals
If on remdesivir, follow daily LFTs and eGFR
If not on RDV, may reconsider if progresses and/or continues to qualify via the ID consult pager
Other off-label therapies can be considered with guidance from ID

Refer to MGH ICU COVID management guidance
If on RDV, follow daily LFTs and eGFR
Decisions about off-label immunomodulatory or other therapies can be considered on a case-by-case basis by the ICU team, with ID guidance

*: See risk factors table (Table 2) in this document
†: Current list of clinical trials is found at this link.
ID strongly recommends referral to clinical trials
‡: Guidance from ID regarding off-label use of immunomodulators or compassionate/emergency use remdesivir is available 8am to 8pm
§: Clinical trials may include RDV, may specifically exclude RDV or allow for open label RDV from EUA or compassionate use. If the trial excludes RDV, the patient may or may not decide to de-enroll should they qualify under the EUA
❖: If not on RDV (eg declined or not qualified earlier in admission), regardless of clinical trial enrollment status, patient may be reconsidered for RDV should they qualify under the EUA.